Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )

Inclusion Criteria: * Has histologically confirmed recurrent disease or metastatic SCCHN tumor and/or from its lymph nodal metastases originating from the oral cavity, oropharynx, hypopharynx, and larynx * Has or be willing to provide tumor tissue for testing * Has measurable disease per Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 * Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Has adequate hematological function per protocol * Has adequate renal function per protocol * Has adequate hepatic function per protocol * Agrees to use effective contraception while on the study and for 6-months after the end of the study * Provides written informed consent(s) Exclusion Criteria: * Has left ventricular ejection fraction (LVEF) \<50% * Had prior epidermal growth factor receptor (EGFR) targeted regimen * Had prior anti-human epidermal growth factor receptor 3 (anti-HER3) therapy * Had prior chemotherapy for recurrent/metastatic disease * Had anti-cancer therapy between biopsy and submission of sample * Has history of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 2 years * Has known history of brain metastases or active brain metastases * Has uncontrolled hypertension * Has clinically significant electrocardiograph (ECG) findings * Had myocardial infarction within 1 year before enrollment, symptomatic congestive heart failure, unstable angina, or arrhythmia requiring medication * Had platinum-containing drug therapy with radiotherapy less than 6 months before study drug treatment * Had therapeutic or palliative radiation therapy or major surgery within 4 weeks before study drug treatment